Parkinson's Disease Biomarkers Program (PDBP)
The National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Biomarkers Program (PDBP) was developed to accelerate the discovery of promising new diagnostic and progression biomarkers for Parkinson's disease.
Although our understanding of the biology and genetics associated with Parkinson's disease (PD) is advancing rapidly, gaps remain between promising laboratory discoveries and the realization of treatments that will cure or slow progression of PD. To address the needs of the PD community, the National Institute of Neurological Disorders and Stroke (NINDS) has established the PDBP to focus on promoting the discovery of biomarker candidates for early detection and measurement of disease progression. The PDBP will coordinate the efforts of multiple stakeholders through a common Data Management Resource and web portal. The PDBP will serve as a multi-faceted platform for:
- Integrating existing biomarker efforts
- Standardizing data collection and management across these efforts
- Accelerating the discovery of new biomarkers
- Fostering and expanding collaborative opportunities for all stakeholders
The PDBP will support both clinical and laboratory-based discovery projects leading to the advancement of PD candidate markers for pre-symptomatic diagnosis and monitoring of disease progression. These biomarkers will ultimately be critical for designing effective Phase II and III clinical trials.
The PDBP has three major components:
Research Projects: Funding opportunities (FOAs) support discovery projects designed to promote the identification of promising diagnostic and progression biomarkers for Parkinson's disease. Examples of such projects include, but are not limited to: 1) development of laboratory-based assays for assessment of candidate markers, 2) development of new statistical and analytical software programs to enable analysis of complex datasets; and 3) development and utilization of new and existing, well-defined cohort studies that cross all stages of Parkinson's disease to identify clinical, pathological, or imaging biomarkers for disease onset or progression.
Biospecimen Repository: The NINDS Repository will facilitate the banking and distribution of biological samples collected under a standardized set of procedures designed to ensure the quality of the biospecimens collected. Researchers focused on PD biomarker discovery will have access to these samples and associated clinical data and will share the outcomes of their biomarker discovery projects with the broader PD research community.
Data Management Resource (DMR):The PDBP Data Management Resource will provide software solutions for electronic data entry and clinical site management, which in turn will facilitate the receipt, quality control, and processing of all standardized clinical, imaging, biological, and molecular data from Parkinson's disease biomarker projects. This database of PD clinical, imaging, molecular and biological information will be shared with the broader research community to promote further discoveries advancing clinical breakthroughs for Parkinson's disease.